Novartis Recognizes Rare Disease Day - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis Recognizes Rare Disease Day


Novartis joined the global rare-disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need. Rare Disease Day is an annual, international awareness-raising event coordinated globally by Rare Diseases Europe (EURORDIS) and in the US by the National Organization for Rare Disorders (NORD) and held on the last day of February. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.

"Novartis is pleased to help raise the dialogue about rare diseases and the need for more research to understand these diseases better," said Dr. Mark Fishman, President of the Novartis Institutes for BioMedical Research, in the press release. "Our focus on rare diseases flows from our desire to help patients underserved by today's medicines. In addition, research into rare diseases teaches us fundamental mechanisms of human biology and disease, often applicable to more prevalent disorders."  Novartis has nine marketed drugs that have been designated orphan drugs as well as more than 40 active preclinical and clinical research projects in the rare diseases area. Novartis has also established alliances with more than 300 collaborators, both academic and industrial, many focused on rare diseases.

Novartis will sponsor and host RE(ACT) Congress 2014, the second international conference on research of rare and orphan diseases, organized by the Gebert Rüf Foundation and the Blackswan Foundation. The meeting, held on the Novartis Basel Campus from March 5–8, 2014, provides the global research community with a platform to connect, exchange ideas, and deepen fundamental understanding of rare diseases.

Source: Novartis

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here